LGHTvsBBHETF Comparison
Langar Global HealthTech ETF (LGHT) belongs to the Healthcare Technology segment. VanEck Biotech ETF (BBH) is part of the US Health Care segment. Both ETFs have the same top 1 sector exposures: Healthcare. LGHT is more expensive with a Total Expense Ratio (TER) of 0.85%, versus 0.35% for BBH. LGHT is up 2.6% year-to-date (YTD) with -$1M in YTD flows. BBH performs better with 26.63% YTD performance, and +$2M in YTD flows. Run a side-by-side ETF comparison of LGHT and BBH below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
LGHT vs BBH performance and flow charts
Performance
Cumulative Flows
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | LGHT BBH | +15.51%+17.26% | +25.50%+28.71% | +2.60%+26.63% | +0.98%+44.64% | n/a+47.93% | n/a+12.61% |
| Flows | LGHT BBH | -+$10M | -$522K+$9M | -$1M+$2M | -$941K-$21M | --$154M | --$135M |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | LGHT BBH | +38.13%+27.60% | +25.51%+21.66% | n/a+20.13% | n/a+21.76% |
| Max drawdown | LGHT BBH | -10.33%-5.29% | -25.58%-10.54% | n/a-22.78% | n/a-39.56% |
| Max drawdown duration | LGHT BBH | 32d30d | 309d150d | n/a440d | n/a1795d |
LGHT | BBH | |
Last sale 9/2/2026 at 1:30 PM | $242.79 | |
| Previous close 09/01/2026 | $239.49 | |
| Consolidated volume 09/01/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
LGHT | BBH | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
LGHT | BBH | |
|---|---|---|
| Last price | – | $242.79 |
| 1D performance | – | +1.38% |
| AuM | $2.36 M | $475.89 M |
| E/R | 0.85% | 0.35% |
LGHT | BBH | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | Langar Investment Management | VanEck |
| Benchmark | - | MVIS US Listed Biotech 25 Index |
| N° of holdings | 30 | 24 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | January 10, 2024 | December 20, 2011 |
| ESG | Yes | No |
Countries
Sectors
Diversification
Total weight of top 15 holdings out of 15
Total weight of top 15 holdings out of 15
